The emerging role of digital health in the management of asthma.

Publication Year: 2023

DOI:
10.1177/20406223231209329

PMCID:
PMC10657529

PMID:
38028951

Journal Information

Full Title: Ther Adv Chronic Dis

Abbreviation: Ther Adv Chronic Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Dr. AK declares that he has received consulting fees from AstraZeneca, Bellus, Covis Pharma, Eisai, GlaxoSmithKline, Pfizer, Merck Frost, Sanofi, Teva, Trudel, and Valeo. He has received honoraria from AstraZeneca, Boehringer Ingelheim, Covis Pharma, Cipla, Eisai, GlaxoSmithKline, Merck Frosst, Novo Nordisk, Moderna, Pfizer, Sanofi, Teva, Trudel, and Valeo. He received a FENO machine from Sanofi as part of a severe asthma survey. Mr. MB declares that he has received honoraria as a speaker and consultant for CHE activities from Pfizer, Novo Nordisk, Khiron, Johnson & Johnson, AbbVie, Teva, Biosyent, Boehringer Ingelheim, Moderna, Canopy, and Valneva. He has also been a consultant for CHE activities on advisory boards for Novo Nordisk, Emergent BioSolutions, Pfizer, and Novamax. Dr. JB declares that he has no competing interests in association with this manuscript. Dr. JK declares that he received grants/contracts from Novo Nordisk. He received consulting fees from Abbott, AbbVie, AstraZeneca, Bayer, BD, Boerhinger Ingelheim, Eisai, Embecta, Eli Lilly, GlaxoSmithKline, Janssen, Novo Nordisk, Miravo Pharm, Teva, Takeda, and Sanofi. He has received honoraria from Abbott, AbbVie, AstraZeneca, Boerhinger Ingelheim, Eisai, Embecta, Eli Lilly, GlaxoSmithKline, Janssen, Novo Nordisk, Miravo Pharm, Moderna, Pfizer Takeda, Sanofi, and Otsuka. Dr. SH declares that he received an honorarium as a workshop facilitator for Teva. Dr. CL declares that his institution has received grants/contracts from AstraZeneca, the Ontario Ministry of Health, Canadian Institutes of Health Research, and the Federal Economic Development Agency for Southern Ontario. His company has received payment/honoraria from AstraZeneca, Boerhinger Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, and Valeo. He has participated in advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Sanofi Genzyme, and Teva."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Editorial assistance with the preparation of this manuscript was funded by Teva Canada."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025